JPWO2020210232A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020210232A5
JPWO2020210232A5 JP2021559648A JP2021559648A JPWO2020210232A5 JP WO2020210232 A5 JPWO2020210232 A5 JP WO2020210232A5 JP 2021559648 A JP2021559648 A JP 2021559648A JP 2021559648 A JP2021559648 A JP 2021559648A JP WO2020210232 A5 JPWO2020210232 A5 JP WO2020210232A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525435A (ja
JP2022525435A5 (https=
JP7730295B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027071 external-priority patent/WO2020210232A1/en
Publication of JP2022525435A publication Critical patent/JP2022525435A/ja
Publication of JP2022525435A5 publication Critical patent/JP2022525435A5/ja
Publication of JPWO2020210232A5 publication Critical patent/JPWO2020210232A5/ja
Application granted granted Critical
Publication of JP7730295B2 publication Critical patent/JP7730295B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559648A 2019-04-08 2020-04-07 Ｃｄ１９抗体およびこれを使用する方法 Active JP7730295B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831123P 2019-04-08 2019-04-08
US62/831,123 2019-04-08
PCT/US2020/027071 WO2020210232A1 (en) 2019-04-08 2020-04-07 Cd19 antibodies and methods of using the same

Publications (4)

Publication Number Publication Date
JP2022525435A JP2022525435A (ja) 2022-05-13
JP2022525435A5 JP2022525435A5 (https=) 2023-04-13
JPWO2020210232A5 true JPWO2020210232A5 (https=) 2023-04-13
JP7730295B2 JP7730295B2 (ja) 2025-08-27

Family

ID=72751761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559648A Active JP7730295B2 (ja) 2019-04-08 2020-04-07 Ｃｄ１９抗体およびこれを使用する方法

Country Status (8)

Country Link
EP (1) EP3953385A4 (https=)
JP (1) JP7730295B2 (https=)
KR (1) KR20220006065A (https=)
CN (1) CN114341176A (https=)
AU (1) AU2020270888A1 (https=)
CA (1) CA3136251A1 (https=)
IL (1) IL287039A (https=)
WO (1) WO2020210232A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
LT4269444T (lt) 2020-08-14 2024-09-25 GammaDelta Therapeutics Limited Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
CA3214628A1 (en) * 2021-04-06 2022-10-13 Memorial Sloan-Kettering Cancer Center Combination therapy with dexamethasone and tumor-specific t cell engaging multi-specific antibodies for treating cancer
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
JP2024546804A (ja) * 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド Ｓａｄａ複合体を含む製剤
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
AU2024359838A1 (en) * 2023-10-13 2026-04-23 Suzhou Ribo Life Science Co., Ltd. Conjugate, drug conjugate and composition, and preparation method and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398829A2 (en) * 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN110267982B (zh) * 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
SG10201912400VA (en) * 2017-04-24 2020-02-27 Kite Pharma Inc Humanized antigen-binding domains against cd19 and methods of use
AU2018337142B2 (en) * 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
US11555072B2 (en) * 2017-09-23 2023-01-17 Memorial Sloan Kettering Cancer Center A33 antibody compositions and methods of using the same in radioimmunotherapy

Similar Documents

Publication Publication Date Title
Paul et al. Cancer therapy with antibodies
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
KR101115797B1 (ko) 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
Welt et al. Phase I study of anticolon cancer humanized antibody A33
CN102174108B (zh) 内在化抗-cd74抗体和使用方法
AU2009222547B2 (en) Immunotherapy of B cell malignancies and autoimmune disease using unconjugated antibodies and conjugated antibodies, antibody combinations and fusion proteins
JP4733635B2 (ja) 抗ｃｄ１９抗体
Wu et al. Designer genes: recombinant antibody fragments for biological imaging
IL273484B1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
JP2021517816A5 (https=)
JP2020523029A5 (https=)
JP2020534017A5 (https=)
CN117279950B (zh) 一种靶向il-18bp的抗体及其应用
JPWO2020210232A5 (https=)
CN101796073B (zh) 针对cxcr3的人源化抗体
JP2025530159A (ja) Ｃｃｒ８抗体の医学的使用および投与スケジュール
JPWO2021046331A5 (https=)
JPWO2020264211A5 (https=)
JPWO2021216972A5 (https=)
JPWO2022032004A5 (https=)
JPWO2019178218A5 (https=)
CN115368457B (zh) 抗tigit抗体及其用途
TWI889766B (zh) 抗cd19抗體以及使用與製造其的方法
JPWO2023014809A5 (https=)